CaverSTIM™

About Comphya

Comphya is pioneering a restorative neuromodulation approach to address a major unmet need in male sexual health: erectile dysfunction (ED) following prostate cancer surgery. Its lead product, CaverSTIM™, is an implantable system that delivers targeted stimulation to the cavernous nerves during the critical post-surgical recovery window, aiming to support natural nerve healing rather than just managing symptoms. The device is currently in clinical trials, with early data showing promising recovery rates, and is designed for seamless integration into existing robotic prostatectomy workflows. The company targets a significant market opportunity, as current post-surgical ED treatments are often ineffective or invasive.

Therapeutic Areas